초록 ▼

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune d

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

대표청구항 ▼

What is claimed is: 1. A conjugate comprising an anti-tumor drug conjugated to a polyglutamate polymer, wherein said anti-tumor drug is directly linked to said polyglutamate polymer and said anti-tumor drug is selected from the group consisting of a taxoid, etoposide, teniposide, camptothecin and e

What is claimed is: 1. A conjugate comprising an anti-tumor drug conjugated to a polyglutamate polymer, wherein said anti-tumor drug is directly linked to said polyglutamate polymer and said anti-tumor drug is selected from the group consisting of a taxoid, etoposide, teniposide, camptothecin and epothilone. 2. The conjugate of claim 1, wherein said anti-tumor drug is a taxoid. 3. The conjugate of claim 2, wherein said taxoid is paclitaxel. 4. The conjugate of claim 3, wherein the molecular weight of said polyglutamate polymer is about 33,000 daltons. 5. The conjugate of claim 3, wherein the ratio of paclitaxel conjugated per water soluble polymer is about 37%. 6. The conjugate of claim 1, wherein said taxoid is docetaxel. 7. The conjugate of claim 1, wherein said anti-tumor drug is etoposide. 8. The conjugate of claim 1, wherein said anti-tumor drug is teniposide. 9. The conjugate of claim 1, wherein said anti-tumor drug is camptothecin. 10. The conjugate of claim 1, wherein said anti-tumor drug is epothilone. 11. A conjugate comprising an anti-tumor drug conjugated to a polyglutamate polymer, wherein the molecular weight of said polyglutamate polymer is greater than 5,000 daltons and said anti-tumor drug is selected from the group consisting of a taxoid, etoposide, teniposide, camptothecin and epothilone. 12. The conjugate of claim 11, wherein said anti-tumor drug is a taxoid. 13. The conjugate of claim 12, wherein said taxoid is paclitaxel. 14. The conjugate of claim 13, wherein the molecular weight of said polyglutamate polymer is about 33,000 daltons. 15. The conjugate of claim 13, wherein the ratio of paclitaxel conjugated per water soluble polymer is about 37%. 16. The conjugate of claim 12, wherein said taxoid is docetaxel. 17. The conjugate of claim 11, wherein said anti-tumor drug is etoposide. 18. The conjugate of claim 11, wherein said anti-tumor drug is teniposide. 19. The conjugate of claim 11, wherein said anti-tumor drug is camptothecin. 20. The conjugate of claim 11, wherein said anti-tumor drug is epothilone.